Tumor Bacteria + Vitamin B2 Unlock Lung Cancer Immunity

Tumor bacteria may sound like a nuisance. But in one surprising case they hinted at something else: an unusually strong response to lung cancer immunotherapy that tracked with an abundance of a specific immune cell type called MAIT cells. The observation jolted researchers and redirected experiments toward a curious partnership between microbes, a vitamin metabolite, and the immune system.

Researchers found a possible link between abundant MAIT cells and an unusually strong response to lung cancer immunotherapy. The clue is now driving experiments aimed at turning a little-studied immune mechanism into a new treatment strategy. 

A bacterial clue inside tumors

Most immunotherapies are designed to unleash conventional T cells of the adaptive immune system so they recognize and kill tumor cells. But innate immune players exist too, and one family—mucosal-associated invariant T cells, or MAIT cells—has largely flown under the radar in cancer research. MAIT cells specialize in rapid responses to microbial metabolites at mucosal surfaces. Could they be coaxed to fight cancer?

Scientists at Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy followed that question into the tumor microbiome, where bacteria live inside lung tumors. Using microbiome sequencing of human tumor samples, RNA sequencing of immune cells, and cell culture experiments, the team uncovered a biochemical trigger: a metabolite derived from vitamin B2.

When bacteria extracted from lung tumors were exposed to this vitamin B2 metabolite in culture, antigen-presenting immune cells dramatically increased the surface expression of a protein called MR1. MR1 is the molecular handshake MAIT cells use to detect microbial activity. With more MR1 on display, MAIT cells become activated—and activated MAIT cells can act rapidly against perceived threats.

When a metabolite flips a switch

Expectations initially pointed toward bacteria that naturally produce the vitamin B2 metabolite as the key players. Instead the team saw a twist: strains of enterococci that do not themselves synthesize the metabolite nevertheless drove strong MAIT activation when the metabolite was added externally to the cultures. In short: the metabolite plus tumor-associated bacteria raised MR1 levels on antigen-presenting cells and flipped MAIT cells into an active state.

"We are opening a new field of immunotherapy by using a metabolite that, in combination with these bacteria, increases the expression of MR1 and triggers the activation of MAIT cells toward the tumor," says Franck Housseau, Ph.D., PharmD, who leads mucosal immunology work at Johns Hopkins and now directs research at the French National Institute of Health and Medical Research.

Pakhi Birla, Ph.D., the study lead while completing her doctorate, notes the broader implication: "Tumor-associated bacteria may regulate the immune response to tumors by regulating the expression of MR1 on antigen-presenting cells and activating the MAIT cells in the tumor microenvironment, which could have anti-tumor effects."

Members of the Pardoll, Housseau, Sears and Shaikh laboratories at Johns Hopkins who contributed to the study. 

Why this matters for immunotherapy

In earlier clinical work at Johns Hopkins, one lung cancer patient who received neoadjuvant PD-1 blockade immunotherapy before surgery showed an unusually strong tumor response—and that patient had an abundance of MAIT cells in tumor samples. That retrospective clue suggested MAIT cells might contribute meaningfully to therapeutic success in some patients.

Current T cell therapies—like engineered CAR-T cells—are typically personalized, expensive, and focused on proteins unique to each tumor. MR1 offers a different possibility: it presents microbial-derived molecules, and MR1 itself is a conserved protein that could, in principle, be targeted across patients. If adaptive immune cells can be trained or engineered to recognize MR1-displayed signals on tumor-associated antigen-presenting cells, an MR1-based strategy could be a more broadly applicable, off-the-shelf option.

The Johns Hopkins team has already launched preclinical studies. One line of work tests whether injecting the vitamin B2 metabolite directly into lung tumors in mice provokes a local immune response. Another explores whether adaptive T cells can be engineered to seek MR1-presented markers so they will act across diverse patients rather than one at a time.

Expert Insight

"The tumor microenvironment is not a sterile battlefield; microbes and their metabolites can profoundly influence which immune cells show up and how they behave," says Dr. Marina Koval, an immuno-oncology researcher not involved with the study. "What’s compelling here is the modularity: a small metabolite plus bacteria alter MR1 expression, and that sets MAIT cells into motion. That could be leveraged in multiple therapeutic formats—small molecules, microbial engineering, or cell therapies."

Dr. Koval adds a practical note: "Translating this will require careful safety work. Stimulating innate-like T cells can be powerful, but you must avoid excessive inflammation in lung tissue. Still, the concept broadens the toolbox for lung cancer immunotherapy."

Technical context and next steps

MAIT cells detect vitamin B2–related metabolites presented by MR1, distinguishing microbial metabolic activity from normal host signals. That molecular logic—microbe-derived small molecules displayed on host proteins—explains why the same metabolite can boost immune activation even when produced by one microbe but presented in the context of another.

Future experiments will map which bacterial species, and which combinations of bacteria plus metabolite, are most effective at raising MR1 levels in the tumor microenvironment. The researchers also plan safety and efficacy studies in animal models before any clinical translation. Parallel efforts will explore MR1-directed adaptive T cells: if they can be engineered to recognize MR1 presentation reliably, that could produce a tumor-agnostic therapy.

Conclusion

The study reframes tumor-resident bacteria from passive residents to potential collaborators in immune activation. By leveraging a simple vitamin B2 metabolite to raise MR1 expression and engage MAIT cells, researchers have opened a new line of inquiry in cancer immunotherapy—one that might yield therapies that are cheaper, less personalized, and widely applicable across patients with lung cancer. The work remains preclinical, but it reframes how microbes, metabolites, and immune cells interact inside tumors, and it points toward practical experimental pathways for new treatments.